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Abstract
Background: Chronic fatigue syndrome, also known as ME (CFS/ME), is a condition characterised primarily by severe, disabling
fatigue, of unknown origin, which has a poor prognosis and serious personal and economic consequences. Evidence for the
effectiveness of any treatment for CFS/ME in primary care, where most patients are seen, is sparse. Recently, a brief, pragmatic
treatment for CFS/ME, based on a physiological dysregulation model of the condition, was shown to be successful in improving
fatigue and physical functioning in patients in secondary care. The treatment involves providing patients with a readily
understandable explanation of their symptoms, from which flows the rationale for a graded rehabilitative plan, developed
collaboratively with the therapist. The present trial will test the effectiveness and cost-effectiveness of pragmatic rehabilitation
when delivered by specially trained general nurses in primary care. We selected a client-centred counselling intervention, called
supportive listening, as a comparison treatment. Counselling has been shown to be as effective as cognitive behaviour therapy
for treating fatigue in primary care, is more readily available, and controls for supportive therapist contact time. Our control
condition is treatment as usual by the general practitioner (GP).
Methods and design: This study protocol describes the design of an ongoing, single-blind, pragmatic randomized controlled
trial of a brief (18 week) self-help treatment, pragmatic rehabilitation, delivered by specially trained nurse-therapists in patients'
homes, compared with nurse-therapist delivered supportive listening and treatment as usual by the GP. An economic evaluation,
taking a societal viewpoint, is being carried out alongside the clinical trial. Three adult general nurses were trained over a six
month period to deliver the two interventions. Patients aged over 18 and fulfilling the Oxford criteria for CFS are assessed at
baseline, after the intervention, and again one year later. Primary outcomes are self-reported physical functioning and fatigue at
one year, and will be analysed on an intention-to-treat basis. A qualitative study will examine the interventions' mechanisms of
change, and also GPs' drivers and barriers towards referral.
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Chronic fatigue syndrome, also known as ME (CFS/ME),
is a symptomatically-defined condition in which the main
complaint is medically unexplained fatigue, lasting at
least six months, and of sufficient severity to impair the
patient's functioning substantially [1,2]. The estimated
prevalence in UK primary care ranges from 0.6–2.6%,
depending on the criteria applied [3], while an Independ-
ent Working Party reporting to the UK Chief Medical
Officer in 2002 suggested a UK population prevalence of
0.2–0.4% [4]. CFS/ME patients suffer more functional
impairment than patients with Type 2 diabetes, acute
myocardial infarction and multiple sclerosis [5]; they are
also likely to stop working and to be heavy users of health
care [6]. When conservatively treated, the prognosis for
CFS/ME is poor [7,8]. The cost to society of failing to treat
CFS/ME is considerable; in one primary care study,
women with fatigue were over five times more likely to
have no paid work than women in a matched comparison
group [9].
A 2001 systematic review of all treatments for CFS/ME
concluded that cognitive behaviour therapy (CBT) and
graded exercise therapy (GET) were the most promising
treatments for CFS/ME, but that owing to the small
number of studies available for review, the generalisabil-
ity of these results could not be assured [10]. The authors
recommended that further studies be carried out using
standardised outcome measures. A Cochrane Collabora-
tion systematic review of 13 RCTs of CBT for CFS [11]
reported that only 3 trials met inclusion criteria for the
review. Of these three trials, two showed that hospital-
based CBT was an effective treatment [12,13], a conclu-
sion supported by a subsequent hospital-based trial of
CBT [14]. Unfortunately, however, cognitive behaviour
therapy is not a practical option in many parts of the UK
because there are few therapists with the training and
experience to carry it out [15]. Graded exercise therapy has
also been shown to be effective in randomised controlled
trials with selected hospital patients [16], and in our own
previous study with a more general sample of hospital
patients [17]. It is simpler than CBT to teach, but may not
always be acceptable to patients [18]. Since the research
described in this protocol was funded, two further trials of
GET have been published, in secondary care or university
settings, one of which showed improvements in global
clinical outcome and fatigue [19], the other of which did
not [20].
It has recently been suggested that more research is
needed before we can be confident that effective second-
ary care treatments for CFS/ME can be extrapolated to pri-
mary care [21]. A randomised trial carried out in primary
care compared CBT and counselling for chronic fatigue
(28% of patients fulfilled criteria for CFS). Although the
two treatments were found to be equally effective [22], the
CBT was more expensive than counselling [23], and no
treatment as usual comparison was included. Subse-
quently, in another equivalence trial, CBT and GET were
compared in a primary care sample of chronically fatigued
patients, 29% of whom met criteria for CFS. Again, the
two treatments were found to be equally effective, but
once again, they were not compared with a treatment as
usual control group [18]. A self-help manual was shown
to be more effective than no treatment for a community
sample of patients with chronic fatigue, but only 18% of
the sample fulfilled diagnostic criteria for CFS [24]. Most
recently, and since the present trial was funded, a Dutch
primary care trial has been reported in which general prac-
titioners received brief training to deliver CBT to fatigued
employees on sick leave, 44% of whom probably met
research diagnostic criteria for CFS [25]. The CBT inter-
vention was no more effective than GPs' usual care in
reducing fatigue or returning patients to work.
To our knowledge, therefore, no adequately controlled
trial of treatment for chronic fatigue syndrome in primary
care has been published to date. Those treatments that
have been shown to be effective in secondary care are not
widely available. If a brief, readily communicable and eas-
ily implementable treatment could be shown to be clini-
cally effective and cost effective in primary care, this
would benefit the large proportion of patients who cur-
rently receive no effective treatment, including patients
who might have difficulty accessing secondary care serv-
ices.
We previously reported on a large-scale hospital-based
trial in Liverpool, with out-patients suffering from CFS/
ME, of a treatment termed "pragmatic rehabilitation"
[26]. The treatment is based on a model proposing that
CFS/ME is best understood as a consequence of physio-
logical dysregulation associated with inactivity and distur-
bance of sleep and circadian rhythms [27]. We have
argued that these conditions may be provoked by a
number of biological and psychological factors but are
often maintained by illness beliefs that lead to exercise-
avoidance. The essential feature of the treatment is the
provision of a detailed explanation for patients' symp-
toms, couched in terms of the physiological dysregulation
model, from which flows the rationale for a graded return
to activity. The explanations for various symptoms of CFS/
ME highlight the interaction between psychological and
biological factors. They are given to the patient both ver-
bally during an initial discussion with the therapist and in
the form of a fully-referenced manual, which has been
developed in close collaboration with patients who have
successfully completed the treatment. Having taken con-
trol of their symptoms through a programme of graded
activity, normalisation of sleep patterns, and simple anxi-Page 2 of 12
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to consider the role of psychological and social factors in
their condition.
In the Liverpool trial, three treatment groups received the
manual and varying amounts of contact with a therapist
over a three-month period; either nine face-to-face ses-
sions (maximum treatment), two face-to-face sessions
and seven telephone calls, or two face-to-face sessions
only (minimum treatment). Results showed that all of
these treatments were very effective when compared with
medical assessment and advice: 57% of patients in the
treatment groups no longer fulfilled case criteria for CFS
12 months after starting treatment, as compared with 6%
of patients in the control condition [26]. Analysis of 2-
year follow-up data has now taken place. This shows that,
while all three treatment groups maintained substantial
and clinically significant gains, there was a non-significant
trend for those in the minimum treatment group to show
deterioration in physical functioning and fatigue scale
scores, suggesting that at least the medium amount of
treatment should be given [28].
Our results [26] indicate that pragmatic rehabilitation is
an effective treatment for hospital-based patients. The
treatment trial protocol reported here was designed to
determine whether pragmatic rehabilitation is effective in
primary care settings, when delivered by non-specialist
nursing staff who have received brief training. We decided
to test pragmatic rehabilitation against two treatments, a
patient-centred counselling treatment called supportive
listening, and treatment as usual by the GP. As noted
above, counselling has been shown to be as effective as
CBT for chronic fatigue in primary care [22], but has not
been tested for chronic fatigue syndrome. It is a treatment
from which patients can be expected to benefit and will
also control for supportive therapist contact time.
Aims of the study
This study was designed to address four principal research
questions:
(1) Is pragmatic rehabilitation, delivered at home by
nurses to CFS/ME patients recruited from primary care, a
clinically effective intervention in terms of reduced disa-
bility and fatigue when compared with treatment as usual
delivered through the primary care team?
(2) Is supportive listening, delivered at home by nurses to
CFS/ME patients recruited from primary care, a clinically
effective intervention in terms of reduced disability and
fatigue when compared with treatment as usual delivered
through the primary care team?
(3) Which of the three treatments, pragmatic rehabilita-
tion, supportive listening and treatment as usual, is the
most cost-effective?
The study will also address three further issues: the relative
efficacy and cost-effectiveness of pragmatic rehabilitation
and supportive listening; the mechanism of action of
these treatments; and barriers to the implementation of
these treatments in UK primary care settings.
Methods and design
Design
This is a single-blind pragmatic randomised controlled
trial of a brief (18-week) self-help treatment, called prag-
matic rehabilitation, for CFS/ME patients recruited from
primary care, delivered by three specially trained nurse-
therapists in the patients' homes, and compared with
both nurse-therapist delivered supportive listening, a
comparison treatment that also controls for therapist con-
tact time, and treatment as usual by the General Practi-
tioner.
Setting
The study is currently taking place across the North West
of England. Patients are referred to the trial by their gen-
eral practitioners and assessed in their own homes. If ran-
domised to pragmatic rehabilitation or supportive
listening, patients are treated at home.
Ethical approval
This study has been reviewed and approved by the Eastern
MREC (reference 03/5/62)
Training the nurse therapists to deliver the interventions
The three nurse-therapists delivering the pragmatic reha-
bilitation and supportive listening treatments were
employed specifically to work on this trial. We decided to
recruit three nurses (adult registered general nurses, RGN)
with an interest in psychosocial aspects of health care (e.g.
district nurses, practice nurses), who were used to working
in the community and primary care, and who could man-
age medical co-morbidity, in order to develop a treatment
that could be made widely available. Primary care general
nurse practitioners have been successfully trained to
implement interventions based on cognitive behaviour
therapy for patients who were high utilisers of medical
care and had medically unexplained symptoms [29] and
irritable bowel syndrome [30]. We had experience of
training practice nurses to assess and manage anxiety dis-
orders [31], and of training mental health professionals,
including nurses, to deliver individual problem-solving
treatment and a group educational programme to primary
care patients with depression [32]. In addition, we had
experience of training a non-specialist nurse to deliverPage 3 of 12
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service.
Training of the nurse therapists to deliver both interven-
tions took place over a six-month period. Training in each
intervention took place over a period of four months.
Training in the supportive listening intervention started
first. After two months, training in the pragmatic rehabil-
itation intervention started, so that there was a period of
overlap when both interventions were being taught and
practised together.
Training in the supportive listening treatment was pro-
vided by an experienced counsellor with expertise in the
client-centred counselling approach, and was supported
by a training manual specially written for this study. Six-
teen half-days of training were provided, in which the
nurse-therapists were introduced to the techniques and
concepts of client-centred counselling, and developed and
practised new skills using exercises, discussions and role-
plays.
Sixteen half days of training in the techniques of prag-
matic rehabilitation were delivered over a twelve week
period by members of the trial team, working with the
extensive training materials developed by Dr. Pauline
Powell. A particular focus of the pragmatic rehabilitation
training was on teaching the nurses to work with the
patient manual and on equipping the nurses with the nec-
essary skills to enable patients to use the manual effec-
tively. Audio-taped role-play and other practical exercises
were used. During the training period, the nurse-thera-
pists also "shadowed" Pauline Powell and her co-workers
in the hospital setting in order to gain additional experi-
ence.
The nurse therapists were provided with diaries to record
their achievements during the training period. Before the
nurses started treating patients, they practised the skills
that they had learned in training by delivering the sched-
uled treatments to four volunteer patients each. These ses-
sions were audiotaped (with the patients' permission)
and the tapes, together with material generated by the
patients and the nurses, were assessed to evaluate nurses'
practice in accordance with pre-defined criteria relating to
knowledge, skills and attitude [31].
The nurse therapists are receiving regular supervision
while they are treating patients. For the pragmatic rehabil-
itation arm, supervision is provided by two members of
the trial team, while supervision for the supportive listen-
ing arm is being provided by a counsellor experienced in
supervision. In both arms, there is a mixture of group and
individual supervision sessions, and supervision takes
place at approximately two-weekly intervals. Booster
training sessions are being provided in both treatment
arms at approximately four-monthly intervals.
The participants – inclusion and exclusion criteria
Patients aged 18 and over who fulfil the Oxford criteria for
CFS [1] are eligible for inclusion in the trial, with no upper
age limit. These criteria require that patients have a princi-
pal complaint of severe, unexplained fatigue, of new
onset, persisting or relapsing over a period of at least six
months, which results in a substantial impairment to pre-
vious levels of activity and affects both mental and physi-
cal functioning. We have chosen the Oxford criteria for
inclusion as they are simpler for GPs to operate than the
CDC criteria [2], but at baseline assessment we also ascer-
tain whether patients meet the slightly more restrictive
CDC diagnostic criteria. The CDC criteria, in addition to
the above, require that patients have at least four from a
list of eight other symptoms, concurrent with the fatigue
[2]. We also record whether patients fulfil London ME cri-
teria at baseline [33]. We decided not to use the recently
published Canadian criteria [34], as these have not yet
been validated for research purposes. Both the CDC and
the Oxford criteria require that possible medical and psy-
chiatric causes for fatigue are excluded by the taking of a
thorough history, physical examination and a battery of
tests. Participating GPs are provided with a brief protocol
to enable them to carry out these assessments. As GPs may
experience difficulty in determining patients' levels of
activity, we require that patients are sufficiently function-
ally impaired to score 70% or less on the SF-36 physical
functioning scale [35]. Additionally, patients are required
to score 4 or more on the 11-item Chalder fatigue scale
[36]. In accordance with the Oxford and CDC criteria
[1,2], patients whose fatigue is explained by any active
medical condition are excluded, as are patients with schiz-
ophrenia, bipolar disorder, dementia, eating disorders or
substance abuse. Patients with active suicidal ideation (i.e.
within the last month) or with antisocial, borderline or
paranoid personality disorders are excluded because our
nurse therapists are not trained to treat these conditions.
The following patients are also excluded: patients who
cannot read or write English sufficiently well to participate
in treatment or complete the assessment measures;
patients who are incapable of giving informed consent;
patients who are currently undertaking systematic psycho-
logical therapies for CFS/ME or who have received prag-
matic rehabilitation therapy within the past year. Patients
with mild to moderate depression and/or anxiety disor-
ders are not excluded. Patients with comorbid conditions
(for example, orthopaedic problems) that might be exac-
erbated by the activity programme are not excluded, but
the advice given to them is tailored accordingly.Page 4 of 12
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There are three treatment arms: pragmatic rehabilitation,
supportive listening, and treatment as usual by the general
practitioner. Three nurse-therapists deliver the pragmatic
rehabilitation and supportive listening treatments in
patients' homes and via telephone calls. All three nurse-
therapists deliver both treatments. Each patient in the
pragmatic rehabilitation and supportive listening arms is
treated by only one nurse therapist. The schedule of ther-
apist contact is identical in the two treatment arms. The
treatment period is eighteen weeks.
Pragmatic rehabilitation and supportive listening treat-
ments each consist of five face-to-face sessions delivered
in the patient's home (on weeks 1, 2, 4, 10 and 19), inter-
spersed with five 30-minute telephone calls to the patient
(on weeks 3, 6, 8, 12 and 15), in accordance with a stand-
ard operating protocol. The first face-to-face session lasts
approximately 90 minutes, while the other four face to
face sessions last approximately 60 minutes. The tele-
phone calls last a maximum of 30 minutes. A record is
kept of the dates on which treatment sessions are deliv-
ered, and of the length of each session.
We needed a longer first face-to-face session to allow time
for the delivery of the rationale for pragmatic rehabilita-
tion and supportive listening. While two face-to-face ses-
sions with the therapist were effective in the Liverpool
secondary care trial [26], patients in that trial first met
with the therapist after an extended consultation with the
consultant physician, which may have had therapeutic
effects. We therefore felt that we needed at least one extra
face-to-face session with the therapist, and decided to
have the fourth home visit in order to be able to treat the
more complex or chronic presentations. The fifth home
visit is a discharge visit and focuses on identifying further
treatment needs and planning for the future. The nurse
therapists keep diaries of their activities during treatment,
and these are used during supervision. We piloted the tim-
ing of the sessions and telephone calls with volunteer
training patients before trial treatment started and found
that these timings were acceptable to both the patients
and the nurse therapists.
The content of pragmatic rehabilitation treatment
The first intervention session is taken up with providing
patients with a detailed explanation of their symptoms in
terms of such physiological explanations as circadian
rhythm desynchronisation, disrupted sleep patterns,
neuro-endocrinological disturbances, and cardiovascular
and muscular deconditioning. The somatic manifesta-
tions of anxiety are also explained to the patient. The
patient is given the manual at this session. Our experience
is that this initial session, which provides patients with
convincing explanations for their symptoms and also
indicates how they can be targeted in treatment, is crucial
to the success of the intervention; in the Liverpool trial the
majority of patients rated this component as very helpful
on a follow-up questionnaire [37]. Patients are then
encouraged to embark upon a series of treatment compo-
nents, including graded exercise (starting at a very low
level and increased very gradually), a return to more regu-
lar sleep patterns, and relaxation exercises. The initial level
of activity is determined collaboratively with the patient,
taking into account the patients' current activity levels,
and always starts at a level less taxing than the patient can
currently manage. During meetings and telephone calls
with the therapist, the rationale for the treatment is rein-
forced, and the patient encouraged to adhere to treatment
using motivational interviewing techniques [38]. Patients
are asked to keep a diary of their progress on the exercise
programme, together with a note of their daily activities,
rest and sleep, and any problems encountered and how
they were dealt with. These diaries, which remain the
property of the patient, are then reviewed at each contact
with the nurse.
The content of supportive listening treatment
We recognise that patients with CFS/ME often feel misun-
derstood or disbelieved, so an important part of any non-
specific treatment effect might be attributable to the
patient feeling that his or her symptoms are being taken
seriously, and that his or her status as an ill person is
accepted. The aim of the supportive listening treatment
arm is to provide emotional support and validation for
the patient through the development of a collaborative
relationship in which the patient is held in unconditional
positive regard, and encouraged to talk about his or her
experience of CFS/ME and problems which he or she has
in dealing with it. The content of patient-therapist discus-
sions is largely determined by the patient. In order to pro-
vide parity with the pragmatic rehabilitation intervention,
patients in the supportive listening arm are provided with
a short manual that explains the principles of client-cen-
tred counselling, provides suggestions as to how to get the
most out the treatment, and includes diary pages for the
patient to record his or her own thoughts and feelings.
The content of treatment as usual by the General Practitioner
GPs usually try to talk to patients such as these about their
symptoms in an unstructured way, investigate, provide
reassurance, prescribe symptomatic relief, prescribe hyp-
notics, sedatives and anti-depressants, and refer. For this
trial, GPs are advised on how to assess CFS/ME patients,
and asked not to refer to specialist services for systematic
psychological therapies for CFS/ME during the eighteen
week treatment period, but are otherwise invited to man-
age their allocated cases as usual in the way that they see
fit. Treatment received by patients from their GPs will be
determined at the end of the trial by examination of GPPage 5 of 12
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received at the 20 and 70 week assessments.
Treatment fidelity
All three therapists deliver both the pragmatic rehabilita-
tion and the supportive listening treatments. We chose
this approach rather than having different therapists deliv-
ering the different therapies in order to reduce the con-
founding of therapist effects. We have a good track record
in trials of CFS/ME [17] and other similar conditions [39]
of achieving fidelity when the same therapist delivers
more than one treatment, and we recognise the impor-
tance of maintaining treatment fidelity in this trial. With
patients' permission, all nurse therapist visits and tele-
phone calls are audio-taped, using digital recorders. We
have developed a schedule for treatment fidelity ratings
and have recruited three independent raters who are rat-
ing a random sample (5%) of the therapy tapes. The tapes
are selected so that: (1) approximately equal numbers
come from each therapist, (2) approximately equal num-
bers of PR and SL are represented and (3) all treatment
sessions are represented, but are otherwise selected at ran-
dom. Tapes are rated blind to treatment classification.
Each tape is classified as one or other treatment, and
receives an overall quality of therapy rating. Additionally,
more detailed ratings of therapeutic alliance, generic ther-
apy quality and treatment-specific therapy quality are pro-
duced, which will be used in subsidiary analyses.
Treatment adherence
Experience from the Liverpool study suggests that patients
who accepted the rationale for treatment were willing to
adhere to it. In the Liverpool study, treatment was com-
pleted by 127/148 patients; i.e. a drop-out rate of only
14%. On the other hand, in a trial of cognitive behaviour
therapy versus counselling for fatigue in primary care [22],
44/193 (35%) eligible patients failed to complete treat-
ment, suggesting that the likely degree of adherence in pri-
mary care may be lower than that seen in hospital care.
Anticipated loss to follow up
In the Liverpool study, 148 patients were randomised to
treatments; each was scheduled to receive four assess-
ments by postal questionnaire (baseline, 3 months, 6
months, one year), making a total of 592 assessments in
all. At the end of the trial, 541 of these assessments had
been completed (including those completed on drop-
outs), giving a loss to follow up of only 9%. Our patients
will be required to complete a larger battery of assess-
ments than those in the Liverpool study, which might
reduce participation rates. On the other hand, we antici-
pate that the fact that interventions and assessment will
take place in the patients' homes in this trial will reduce
both failure to adhere to treatment and failure to com-
plete assessments. To ensure that we have sufficient num-
bers to test our hypotheses, we have estimated a rate of
23% combined non-compliance and loss to follow-up
(this being half-way between the 35% drop out rate
reported in a previous primary care trial [22], and the 9%
loss to follow up in our previous trial). To reduce loss to
follow-up, we plan to ask patients to nominate a relative
or friend who could be contacted to help us to trace them
should they move away.
Some CFS/ME patient support groups have suggested that
activity may be harmful to some CFS/ME patients [4], but
no adverse outcomes have been reported from previous
well-conducted treatment trials that have included ade-
quately graded activity as a component of treatment [4].
The activity programme forming part of pragmatic reha-
bilitation is determined collaboratively by the patient and
therapist, and always starts at a level less taxing than the
patient can currently manage. Similarly, the rate at which
activity is increased and the type of activity undertaken are
determined by the patient in collaboration with the ther-
apist. If there are any adverse reactions, these will be noti-
fied to the independent committees overseeing the trial
(the Data Monitoring and Ethics and Trial Steering Com-
mittees) and to MREC, in accordance with agreed proce-
dures.
Recruitment of patients
After obtaining formal approval from the relevant Primary
Care Trusts, information about the trial is sent to GP prac-
CONSORT diagramFigure 1
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tify patients whom they think may be suitable for the trial
from their patient lists and from new consultations, and
then to assess each patient in accordance with a protocol/
checklist provided in their information pack. The checklist
is based on the Oxford criteria [1] and includes a list of
advised exclusionary tests. If, in the GP's opinion, the
patient fulfils the trial criteria, and the patient agrees, a
referral is sent to the FINE Trial office. A copy of the
Patient Information Sheet and consent form is sent from
the FINE Trial office to the patient, and followed up one
week later by a telephone call from one of the research
team (research assistant or trial manager) during which
the patient can ask questions and decide whether he or
she wishes to be assessed. At the baseline assessment,
which takes place in the patient's home, the trial is
explained again, the importance of maintaining
researcher blindness is emphasised to the patient, and
written informed consent is obtained. The baseline assess-
ment is then carried out. (See Figure 1).
The baseline assessment
The baseline assessment serves two purposes – firstly to
ensure that patients recruited to the trial meet study crite-
ria, and secondly to obtain baseline measures on all our
outcomes. The schedule for the baseline assessment and
subsequent assessments is shown in Table 1. If there is any
doubt as to whether the patient fulfils criteria for entry to
the study, the research assistant consults with medically
qualified members of the team and/or the referring GP,
and if necessary the patient can be referred back to the GP
for further information or tests. Once we are satisfied that
the patient fulfils study criteria, the trial manager notifies
the randomisation service.
Randomisation
Randomisation of individual patients as they are recruited
to the trial is carried out by an independent randomisa-
tion unit based at Christie Hospital in Manchester, in con-
sultation with the trial statistician, and in accordance with
a randomisation protocol. The procedure uses ran-
domised permuted blocks (with randomly-varying block
sizes of 9, 12, 15 or 18), after stratification based on
whether the patient is ambulatory or not (not ambulatory
being defined as using a mobility aid on most days), and
on whether the patient fulfils London ME criteria or not.
There are therefore four strata in total. Where applicable,
patients are assigned to therapists in a simple random
fashion according to the therapists' availability. The trial
manager is informed of randomisation, and group mem-
bership is conveyed to the designated nurse-therapist, if
appropriate. The GP is informed of randomization and
sent a copy of the patient consent form.
Outcome measures
Patients are assessed at entry to the trial (week 0), within
one week of the end of treatment (20 weeks), and then
one year after finishing treatment (70 weeks). Assess-
ments are carried out by trained researchers who are blind
to the arm to which the patient has been randomised.
Assessment at week 70 is required because short-term
assessments of outcome in a chronic health condition
such as CFS/ME can be misleading. Additionally, psycho-
logical treatments such as CBT become more effective over
time [13] and we wish to be able to determine whether
that is the case for our interventions. The primary out-
come point is 70 weeks.
Primary outcome measures
The primary outcome measures are patient-rated to avoid
observer bias. These are (1) score on the physical func-
tioning scale of the SF-36 [35], (2) cost-effectiveness using
the Euroqol [40] and (3) the score on the 11-item Fatigue
Scale [36]. An improvement of 50% or more on the SF-36
physical functioning scale, or a score of 75% or more on
that scale, will be considered a clinically significant
improvement.
Secondary outcome measures
Secondary outcome measures are (1) time to take 20
steps, (or number of steps taken, if this is not achieved)
and maximum heart rate reached on a step-test [41]; (ii)
scores on the anxiety and depression scales of the HADS
[42] to provide measures of depression and anxiety; (iii)
scores a brief four-item sleep scale [43].
Predictors of response to treatment and measures of processes of 
change
In the Liverpool study, scores on the HADS predicted
changes in the primary outcomes, physical functioning
and fatigue. As lack of social support has been implicated
in symptom persistence in chronic fatigue syndrome [44],
we included a brief social support measure [45]. We
administer a visual analogue measure of expectation of
treatment after randomization but before treatment starts.
Beliefs about CFS/ME, particularly physical illness attribu-
tions, predict response to treatment in primary care sam-
ples of patients with fatigue [46]. We administer brief
questionnaire measures of beliefs about illness and the
processes of supportive listening, designed especially for
this study, but based on measures used in the Liverpool
Hospital trial, at each assessment. These brief belief meas-
ures are also administered after the first home visit, to ena-
ble us to assess the impact of the first, rationale-giving
session. We also administer questionnaire measures of
symptom interpretation (Moss-Morris, R & Chalder T,
personal communication) and therapeutic alliance [47].
Our qualitative study will provide a more detailed under-
standing of the processes of change.Page 7 of 12
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Four phases of qualitative interviews are being carried out
with sub-samples of patients and GPs. These will explore
GP and patient attitudes to CFS/ME, its current manage-
ment, and the trial interventions. In addition, we will
determine the mechanisms of action of the interventions
and identify barriers to their implementation. The compo-
sition of the samples will mirror that of the quantitative
study, with representatives of all three treatment groups,
study participators and study refusers, while the exact size
of the sub-samples will be determined during the course
of analysis using the constant comparative technique [48].
The first patient sub-sample will include patients who
have consented to take part in the study. We will use max-
imum variance sampling to generate a range of respond-
ents in terms of age, gender, sociodemographics and
ethnicity, and the sample will include patients entering
each of the three treatment groups. If possible, we will
also interview patients who have refused to take part in
the study, but consented to be interviewed. We anticipate
that approximately 40 interviews will be required. These
first phase qualitative interviews, carried out after the first
quantitative assessment but before treatment commences,
will explore patient views on illness causation, beliefs
about CFS/ME, expectations of intervention and previous
experience of treatment and doctor-patient relationships,
and will provide a comparison for data obtained from the
post-trial qualitative interviews. A second set of interviews
will be carried out towards the end of the trial, with a dif-
ferent subset of patients, in order to investigate the proc-
esses related to successful engagement in and response to
treatment. Sub-samples of patients from the three inter-
vention groups with good and poor outcomes on final
assessment will be selected (approximately 20 of each)
and will be interviewed about their experiences of the
intervention, the value they place on treatment, their rela-
tionship with the therapist, and whether their views on
the causation of CFS/ME changed during the course of
treatment. Patients' views on the effectiveness of the treat-
ment and their plans for management of future health
Table 1: Schedule of assessments and measures administered to patients
Measures Week 0 Week 0 Week 1 Week 10 Weeks 20,70
I = interview SRQ = self-report 
questionnaire O = other
Baseline assessment 
pre-randomization
Post-randomization Following first 
intervention visit
Following week 
10 home visit
Post-treatment 
assessments
Demographics [I] + - - - -
Medical history [I] + - - - -
Oxford criteria [I][1] + - - - +
CDC criteria [I][2] + - - - +
London ME criteria [I][33] + - - - +
SF-36 physical functioning scale 
[SRQ][35]
+ - - - +
Chalder Fatigue scale [SRQ] [36] + - - - +
Hospital Anxiety and Depression 
Scale [SRQ] [42]
+ - - - +
Sleep scale [SRQ][43] + - - - +
Euroqol [SRQ][40] + - - - +
SCID screen for alcohol/substance 
abuse [I][54]
+ - - - -
SCID screen for personality disorders 
[I][55]
+ - - - -
SCID depression and anxiety 
diagnoses [I][54]
+ - - - +
Brief belief measure [SRQ] + - - - +
Brief SL process measure [SRQ] + - - - +
Brief social support measure 
[SRQ][45]
+ - - - +
Symptom interpretation questionnaire 
[SRQ]
+ - - - +
Economic assessment (resource 
use)[I]
+ - - - +
Step test [O][41] + - - - +
Visual analogue scale: treatment 
expectation [SRQ]
- + - - -
CALPAS measure of therapeutic 
alliance [SRQ]
- - + + +Page 8 of 12
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to equality issues in terms of access to and experience of
treatment. Thirdly, qualitative interviews with a represent-
ative sample of GPs who have referred or not referred
patients to the study (approximately 10 of each) will be
performed to explore barriers and drivers towards referral.
Finally, the three nurse therapists were interviewed at the
end of training and prior to starting treatment, and will be
interviewed again at the end of the trial to ascertain their
experience of being trained to deliver these treatments,
and of the treatment process itself.
The economic evaluation
A full economic evaluation is being undertaken alongside
the clinical trial. The economic evaluation takes a societal
viewpoint, but will also disaggregate data to enable us to
examine implications for specific sectors such as primary
and secondary care within the NHS as well other govern-
ment agencies (for example Social Services). Resource-use
data detailing the use of primary and secondary care serv-
ices, social and community services, private and voluntary
services are collected at each assessment point. Unit cost
estimates will then be applied to each resource, using fig-
ures from local providers supplemented by national data
where appropriate. For each patient in the trial, a total cost
will be estimated by calculating the product of resource
use and the relevant unit cost. In addition, cost to patients
(e.g. travel costs) will be estimated at 70 weeks. Cost data
will be analysed using appropriate statistical techniques,
such as bootstrapping, and will also be subjected to exten-
sive sensitivity analysis. A cost-utility analysis will be per-
formed using the EQ5D [40] as a measure of health
related quality of life.
The power analysis for this trial has been based on the
effects expected in the clinical measures. To address the
issue of the adequacy of the sample size to perform the
economic evaluation, methods of presenting data that
allow for the uncertainty created by potentially under-
powered economic evaluations, such as cost-effectiveness
acceptability curves, will be employed. These techniques
allow for the cost of the uncertainty to be estimated and
therefore the value of future data collection can be
assessed.
Power analysis
We plan to recruit 120 patients for each treatment arm.
Our power calculation was based on a comparison
between pragmatic rehabilitation and treatment as usual.
In the Liverpool hospital-based study [26], at 12 months
after the start of treatment, on an intention to treat basis
with previous scores assigned for dropouts, 57% of inter-
vention group patients and 6% of control group patients
were classified as "no longer cases" (i.e. scored 4 or less on
the Fatigue Scale and 75% or more on the SF36 physical
functioning scale). On the basis of previous studies, we
would expect to see a bigger improvement in patients
receiving treatment as usual in primary care [7,9]. We have
also taken a more conservative estimate of the proportion
of patients likely to improve in the pragmatic rehabilita-
tion condition; we believe that a 20% difference in
improvement rates between intervention and control
patients would be of interest to the NHS. A two-group χ2
test with a 0.05 two-sided significance level will have 80%
power to detect the difference between an intervention
group proportion of 50% improved and a treatment as
usual group proportion of 30% improved, when the final
sample size is 93 per group. Allowing for a rate of loss to
follow-up of 23% in the treatment as usual group, the
sample size required is 120 per group.
Analysis plan
Analysis of both the quantitative and qualitative data col-
lected during the course of the trial will take place in
accordance with pre-determined analysis plans, which
have been lodged with the Data Monitoring and Ethics
and Trial Steering Committees.
Analysis of quantitative data
Baseline comparability of the three treatment groups will
be described, but no significance testing will be con-
ducted. Acceptance of and adherence to treatment will be
described. Patients in the pragmatic rehabilitation and
supportive listening arms will be deemed to have accepted
treatment allocation if, after randomization, they embark
on treatment, that is they make themselves available for
the first treatment session. Patients in the treatment as
usual arm will be deemed to have accepted treatment if,
after randomization, they agree to return to their GP's
care. To measure adherence to treatment, in the pragmatic
rehabilitation and supportive listening arms, the number
of home visit sessions and number of telephone calls that
in the opinion of the therapist constituted an intervention
session will be counted. No attempt will be made to assess
adherence further than this. In the absence of any proto-
col violation (e.g. receiving a systematic psychological
therapy for CFS/ME), patients in the treatment as usual
arm will be deemed to have adhered to treatment. Missing
outcome data will be described in relation to patient base-
line characteristics and adherence to treatment.
Descriptive statistics for outcome measures will be pre-
sented. The main analyses will be carried out using all
patients randomized using the principle of Intention-To-
Treat (ITT). With three groups (Pragmatic Rehabilitation –
PR, Supportive Listening – SL and Treatment as Usual –
TAU) we will have two degrees of freedom to test for
group differences. Following a global test to determine
whether the three groups are different, pragmatic rehabil-
itation will be contrasted with supportive listening. IfPage 9 of 12
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pragmatic rehabilitation and supportive listening, they
will be jointly contrasted with treatment as usual. If prag-
matic rehabilitation and supportive listening differ in
their outcomes, then they will be separately compared
with treatment as usual. Effect sizes and confidence inter-
vals will be reported for each group
Sensitivity of the treatment effect estimates to potential
biases arising from missing outcome data will be evalu-
ated by the use of inverse probability weighting [49,50].
This assumes that the missing data mechanism is ignora-
ble – i.e. Missing at Random (MAR). We will also carry out
a likelihood-based analysis of all available data using
Mplus [51] again assuming that the missing data mecha-
nism is ignorable.
A supplementary set of analyses will be undertaken to
assess the effect of non-adherence to allocated treatment
(again taking account of sensitivity to assumed missing
data mechanisms) in order to estimate treatment effects in
those patients who have complied with randomization
(the estimation of the Complier Average Causal Effect –
CACE – as opposed to the Average Causal Effect – ACE –
as estimated using ITT methods). We have provided
detailed examples of this approach elsewhere [52,53].
All analyses to estimate treatment effects will be variations
on an analysis of covariance with the exact form depend-
ing on whether outcome is binary or quantitative. Covari-
ates will include whether the patient is ambulatory or not,
and whether the patient fulfils London ME criteria or not.
Supplementary, exploratory analyses will be carried out to
determine predictors of response to treatment. These will
include, but may not be restricted to, (1) dichotomous
variables such as membership of self-help group, whether
ambulatory or not, whether the patient fulfilled London
ME criteria, presence or absence of psychiatric diagnosis
(e.g. depression); and (2) continuous variables such as ill-
ness duration, score on HAD depression scale, score on
social support scale, and baseline illness beliefs scores.
Analysis will take place once, after data collection is com-
plete. There are no proposed interim analyses.
Trial management and oversight
The day to day management of the trial is carried out by
Trial Manager, Dr Lisa Riste, in consultation with the Prin-
cipal Investigator, Dr Alison Wearden, and other members
of the trial team as necessary. A Trial Management Group
consisting of the grant holders (including Professor Gra-
ham Dunn, the trial statistician), the trial manager and
research assistants meets monthly. Additional meetings
are held to discuss aspects of the pragmatic rehabilitation
and supportive listening therapies, as necessary. Monthly
meetings to monitor trial recruitment are held. The trial is
advised by an independent Trial Steering Committee and
overseen by an independent Data Monitoring Ethics
Committee, both of which meet yearly and operate in
accordance with Medical Research Council Guidelines.
Discussion
Our trial will be the first randomised controlled trial of
treatments for CFS/ME in primary care, and will add to the
knowledge base in a number of ways. We have both a
comparison treatment that controls for supportive thera-
pist contact time and a treatment as usual control arm,
which will help us to assess the efficacy of pragmatic reha-
bilitation. Our trial is conservatively powered, so we can
be confident of detecting clinically significant effects. This
is a pragmatic trial with relatively inclusive entry criteria,
and we anticipate recruiting patients from across the spec-
trum of illness severity. Because we are treating patients in
their homes, we are able to assess and treat patients who
are unable to access secondary care services. These features
will improve the generalisability of our findings.
We have taken a number of steps to protect our trial
against sources of bias. While therapist effects are not a
primary outcome measure in this trial, we have chosen to
use three nurses in order to minimise, or at least observe,
possible therapist effects. To counteract possible biases
introduced by the place of recruitment, all three nurses
treat patients recruited from across the recruitment area.
Differential willingness of patients to be randomised to
treatment as usual is minimised by constraining only sys-
tematic psychological therapies for CFS/ME in the treat-
ment as usual arm of the trial. To reduce observer bias in
assessment, all assessment data are collected by research
assistants not involved in, and blind to, treatment; in
addition, the research assistants are accommodated in dif-
ferent locations from the therapists. All unblindings are
recorded systematically. All outcome measures except the
step-test are patient-rated. Bias and random error in han-
dling data will be minimised by validation checks by the
trial manager on data entry by the research assistants.
If pragmatic rehabilitation is successful in producing a
specific and lasting cost effective clinical benefit, we
expect our findings to have a major impact on training
and services in primary care. We will use our results to
develop educational programmes for primary care health
professionals. If our treatments prove effective and cost-
effective in primary care, we envisage that they would be
deliverable as specialist services provided or commis-
sioned by primary care trusts. We have taken steps to
ensure that our training of nurse therapists in the two
treatments is well-described and replicable, so that train-
ing and service delivery can be implemented later.Page 10 of 12
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